Poloxamer 184 (L64)  (Synonyms: PEG-PPG-PEG, 2900 (Average))

Poloxamer 184 L64 is a block copolymer of polyethylene oxide and polypropylene oxide with an average molecular weight of 2900. Poloxamer has the ability to inhibit P-gp. Poloxamer 184 exhibits short-term skin toxicity, characterized by mild erythema and intradermal inflammatory reactions. Poloxamer 184 has antimicrobial activity, inhibiting 60% of Mycobacterium avium at a concentration of 1 mg/mL. Poloxamer 184 forms a thermoreversible hydrogel and is used as a food additive and as a drug delivery carrier in cosmetics and tissue engineering^[1][2][3].

Poloxamer 184 (1 mg/mL) can inhibit 60% of Mycobacterium avium^[1].
Poloxamer has the ability to inhibit P-gp^[3].
Poloxamer has been proposed as a agent carrier to improve efficacy and reduce side effects^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Poloxamer 184 (up to 1000 mg/kg) causes mild erythema and slight intradermal inflammatory reactions in rabbit skin^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2900 (Average)

9003-11-6

Liquid (Density: 1.095 g/cm³)

Colorless to light yellow

[Poloxamer 184 (L64)]

Room temperature in continental US; may vary elsewhere.

Store at room temperature 3 years

• [1]. Singh-Joy SD, et al., Safety assessment of poloxamers 101, 105, 108, 122, 123, 124, 181, 182, 183, 184, 185, 188, 212, 215, 217, 231, 234, 235, 237, 238, 282, 284, 288, 331, 333, 334, 335, 338, 401, 402, 403, and 407, poloxamer 105 benzoate, and poloxamer 182 dibenzoate as used in cosmetics. Int J Toxicol. 2008;27 Suppl 2:93-128.  [Content Brief]

  [2]. Hunter RL, et al., Enhancement of antibiotic susceptibility and suppression of Mycobacterium avium complex growth by poloxamer 331. antimicrob Agents Chemother. 1995 Feb;39(2):435-9.  [Content Brief]

  [3]. Mello JC, et al. Enhancement of chlorpromazine antitumor activity by Pluronics F127/L81 nanostructured system against human multidrug resistant leukemia. Pharmacol Res. 2016 Sep;111:102-112.  [Content Brief]